This is the third volume of our series Progress in Anti-Cancer Chemoยญ therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribuยญ tions from some of the world's best known leaders in both basic and clinยญ ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of cheยญ motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he proยญ jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impliยญ cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhibยญ itors in research and the therapeutic ramifications
CONTENT
I Conceptual Adances in Cancer Research -- Protecting Human Subjects from Risk in the Performance of Clinical Research and the informed Consent Process -- Progress and Perspectives in the Chemotherapy -- A Personal Perspective About the Future of Breast Cancer Research and Treatmemt -- II Ethic and Fundamental Research in Cancer -- Hereditary Breast Cancer: an overview -- Clinical Apphcations of Angiogenesis inhibitors -- III Lung Cancer -- Current Management and New Leads in Small Cell Lung Cancer -- Progress in Lung Cancer Surgery -- New Drug Combinations in NSCLS: Progress in Cancer Therapy -- IV Urological Tumors -- Update in Testicular Cancer -- Screening for Prostate Cancer: the good, the bad and the ugly -- V Melanoma -- The Development of Cancer Vaccines for the Treatment of Metastatic Melanoma -- The Role of Interferon in the Adjuvant Treatmene of Cutaneous Melanoma -- VI Infectious Agents and Cancers -- Molecular Mechanisms of Hepatitis B and C Viruses related Liver Carcinogenesis -- Epstein-Barr Virus and Malignant Diseases -- Helicobacter Pylori and Malignant Diseases -- VII Advances in solid tumors -- High Risk Soft Tissue Sarcoma: an Overview -- Advances in the Management of Pancreatic Cancer
